Antibiotic therapeutics to combat intestinal pathogen infections often exacerbate microbiota
dysbiosis and impair mucosal barrier functions. Probiotics are promising strategies, because …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Probiotic-based therapy for ulcerative colitis (UC) is a novel and promising approach that
has gained much popularity in recent years. However, probiotics may be easily captured …

The gut microbiota are prominent in preserving intestinal environmental homeostasis and
managing human health, and their dysbiosis has been directly related to many kinds of …

While oral probiotics show promise in treating inflammatory bowel disease, the primary
challenge lies in sustaining their activity and retention within the inflamed gastrointestinal …

Inflammatory bowel disease (IBD) is an incurable disease of the gastrointestinal tract with a
lack of effective therapeutic strategies. The proinflammatory microenvironment plays a …

Oral administration of probiotics is a promising method to alleviate inflammatory bowel
diseases (IBDs). However, gastrointestinal environmental sensitivity and inferior intestinal …

Acute colitis is characterized by the microenvironment with a high level of inflammation,
oxidative stress as well as a disordered microbiome. Sustained delivery of the therapeutic …

Background Ulcerative colitis (UC) is defined by persistent inflammatory processes within
the gastrointestinal tract of uncertain etiology. Current therapeutic approaches are limited in …